<DOC>
	<DOCNO>NCT02932280</DOCNO>
	<brief_summary>The purpose study test safety neratinib different dose level find effect , good bad , patient cancer .</brief_summary>
	<brief_title>Safety Dose Finding Study Neratinib Children Young Adults With Cancer That Has Returned Not Responded Treatment</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>Diagnosis : Pathologic confirmation solid tumor , include central nervous system tumor lymphoma , leukemia Recurrent Refractory Disease effective standard treatment available . Patient must fail least one prior therapy . All patient must evaluable disease define : Solid tumor must lesion evaluable RECIST criterion version 1.1 ; Central nervous system tumor evaluate RANO criterion . Leukemia patient must &gt; 10 % blast ( blast equivalent ) bone marrow Available tissue perform protein genomic analysis Age : Phase 1 : ≥ 6 ≤ 21 year age time enrollment Phase 2 : ≥ 6 ≤ 21 year age diagnosis Body Surface Area requirement vary dose level : Dose Level BSA ( m2 ) 1 ≥ 0.82 1 . ≥ 0.66 2 . ≥ 0.52 3 . ≥ 0.45 Performance level : Lansky score ≥ 60 % ( patient &lt; 16 year age ) Karnofsky score ≥ 60 % ( patient ≥ 16 year age ) Cardiac Function : Patients must shorten fraction ≥ 27 % leave ventricular ejection fraction ≥ 50 % measure echocardiogram ( ECHO ) measure multiplegated acquisition scan ( MUGA ) . Negative βhuman chorionic gonadotropin ( hCG ) pregnancy test female patient childbearing potential ≤ 7 day start neratinib therapy . Female patient reproductive potential must agree commit use highly effective method contraception , determine acceptable investigator , time informed consent 28 day last dose investigational product . Male patient must agree commit use barrier method contraception treatment 3 month last dose investigational product . Written inform consent/assent prior studyspecific procedure . Patient must able swallow tablet exist gastrostomy feed tube enable administration tablet . Patients must recover acute toxic effect prior therapy ≤ grade 1 entering study . Prior therapy HER2 direct TKI ( e.g. , lapatinib , afatinib , dacominib , neratinib , capecitabine ) antiEGFR antibody therapy ( e.g. , cetuximab ) Prior treatment within follow timeframes : Systemic chemotherapy biologic therapy ≤ 2 week 5 half life ( ½ ) agent use , whichever short , prior start neratinib Radiation therapy outside central nervous system ≤ 14 day prior neratinib Radiation central nervous system ≤ 12 week prior initiation neratinib Patients previous allogeneic stem cell transplant ( SCT ) meet either follow criterion : 60 day allogeneic SCT Active acute chronic graftversushostdisease ( GvHD ) receive immunosuppressive therapy treatment GvHD Inadequate marrow function Cohort 1 : Absolute neutrophil count &lt; 1.0 x 10^9 /L Platelets &lt; 100 x 10^9 /L Hemoglobin &lt; 8.0 g/dL ( transfusion permit least 7 day prior baseline ) Inadequate marrow function Cohort 2 These patient marrow function criterion Total bilirubin &gt; 1.5 X upper limit normal ( ULN ) age AST ( SGOT ) ALT ( SGPT ) &gt; 3 X ULN ( unless attribute leukemia involvement ) Serum creatinine &gt; 1.5 X ULN age creatinine clearance ≤ 60mL/min/1.73m^2 Symptomatic unstable brain metastasis . ( Note : Asymptomatic patient metastatic brain disease stable dose corticosteroid treatment brain metastasis least 14 day ( decrease dose corticosteroid ) eligible participate study . ) Patients primary central nervous system tumor eligible . Clinically active cardiac disease , include prolonged QTc interval ≥ 481ms ( i.e . ≥ grade 2 ) Pregnant breastfeed woman Being actively treat concurrent malignancy exception basal cell carcinoma carcinoma situ cervix . Uncontrolled intercurrent illness include , limited uncontrolled infection , unexplained fever &gt; 38.5°C ( 101.3°F ) psychiatric illness/social situation would limit compliance study requirement . Significant chronic gastrointestinal disorder diarrhea major symptom ( e.g. , Crohn 's disease , malabsorption , Grade ≥ 2 National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events Version 4.0 [ CTCAE v.4.0 ] diarrhea etiology baseline ) . Known history human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndrome ( AIDS ) relate disease Known history hepatitis C know active hepatitis B infection Known hypersensitivity component investigational product</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Recurrent</keyword>
	<keyword>Refractory Disease</keyword>
	<keyword>Neratinib</keyword>
	<keyword>16-878</keyword>
</DOC>